Drug

Biostar's Oral Utidelone Capsule Achieves First Patient Dosing in Phase 3 – Non‑Inferiority Bridging Study vs. Marketed Utidelone Injection in HER2‑Negative Advanced Breast Cancer
Biostar TechnologiesClinical trial approval / initiation

Biostar’s Oral Utidelone Capsule Achieves First Patient Dosing in Phase 3 – Non‑Inferiority Bridging Study vs. Marketed Utidelone Injection in HER2‑Negative Advanced Breast Cancer

Beijing Biostar Pharmaceuticals Co., Ltd. (HKG: 2563) announced that its core pipeline asset Utidelone Capsule (UTD2) has successfully achieved first patient dosing in the Phase 3 clinical study (BG02‑2601) for…

Bao Pharmaceuticals’ BJ045 Wins NMPA Clinical Trial Approval – Enzyme‑Resistant Subcutaneous Anti‑CD20 Antibody Engineered for Combination With IgG‑Degrading KJ103

Sanofi and Teva Present 44‑Week RELIEVE UCCD Extension Data – TL1A Antibody Duvakitug Sustains Efficacy Across Ulcerative Colitis and Crohn's Disease Endpoints

Sanofi and Teva Present 44‑Week RELIEVE UCCD Extension Data – TL1A Antibody Duvakitug Sustains Efficacy Across Ulcerative Colitis and Crohn’s Disease Endpoints

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
CMS Announces Phase 3 Success of Ruxolitinib Cream in Atopic Dermatitis
China Medical SystemClinical trial results

CMS Announces Phase 3 Success of Ruxolitinib Cream in Atopic Dermatitis

Leo Pharma Secures First Greater Bay Area Prescription for Anzupgo, a Novel Topical JAK Inhibitor
Auto-immuneBoao Lecheng pilot zone

Leo Pharma Secures First Greater Bay Area Prescription for Anzupgo, a Novel Topical JAK Inhibitor

CSPC Pharma Secures NMPA Approval for Lecanemab Biosimilar, First of Its Kind in China
Clinical trial approval / initiationHKG: 1093

CSPC Pharma Secures NMPA Approval for Lecanemab Biosimilar, First of Its Kind in China

Trump Announces 100% Tariff on Branded Drugs, Exempts U.S.‑Built Pharmaceutical Factories

Trump Announces 100% Tariff on Branded Drugs, Exempts U.S.‑Built Pharmaceutical Factories

Show More